Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. cut its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 31.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,333 shares of the company’s stock after selling 11,797 shares during the period. E Fund Management Co. Ltd.’s holdings in Allogene Therapeutics were worth $59,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of ALLO. Nisa Investment Advisors LLC boosted its holdings in shares of Allogene Therapeutics by 429.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock valued at $25,000 after buying an additional 8,734 shares in the last quarter. Federated Hermes Inc. purchased a new position in shares of Allogene Therapeutics during the second quarter worth about $29,000. Phoenix Wealth Advisors acquired a new stake in shares of Allogene Therapeutics during the second quarter worth about $30,000. Victory Capital Management Inc. lifted its holdings in shares of Allogene Therapeutics by 23.1% in the 4th quarter. Victory Capital Management Inc. now owns 14,283 shares of the company’s stock valued at $46,000 after purchasing an additional 2,680 shares during the last quarter. Finally, RPO LLC acquired a new stake in shares of Allogene Therapeutics in the 4th quarter valued at about $46,000. 83.63% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ALLO shares. Oppenheimer started coverage on Allogene Therapeutics in a research note on Thursday, August 8th. They issued an “outperform” rating and a $11.00 price objective for the company. Truist Financial reiterated a “buy” rating and set a $14.00 price target (down previously from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research note on Thursday, August 15th. Citigroup increased their target price on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Canaccord Genuity Group lowered their price target on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.96.

Allogene Therapeutics Trading Up 1.0 %

NASDAQ ALLO opened at $2.91 on Friday. The stock has a market capitalization of $608.19 million, a price-to-earnings ratio of -1.61 and a beta of 0.83. The business’s 50 day moving average is $2.71 and its two-hundred day moving average is $3.07. Allogene Therapeutics, Inc. has a 12-month low of $2.01 and a 12-month high of $5.78.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative return on equity of 50.24% and a negative net margin of 223,139.98%. Equities analysts forecast that Allogene Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).